uniQure (NASDAQ:QURE) Given Outperform Rating at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of uniQure (NASDAQ:QURE) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a $24.00 target price on the biotechnology company’s stock.

Several other analysts have also recently issued reports on QURE. Stifel Nicolaus increased their price objective on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Leerink Partners increased their price target on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. The Goldman Sachs Group boosted their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Cantor Fitzgerald raised their target price on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. Finally, Mizuho boosted their price target on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.38.

uniQure Stock Performance

NASDAQ QURE opened at $14.91 on Tuesday. The company has a market cap of $726.71 million, a P/E ratio of -3.01 and a beta of 0.41. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock has a 50-day moving average of $12.22 and a two-hundred day moving average of $8.48.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, analysts anticipate that uniQure will post -3.74 EPS for the current year.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC grew its position in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the period. FNY Investment Advisers LLC purchased a new position in uniQure during the 4th quarter worth $88,000. Geode Capital Management LLC increased its stake in uniQure by 1.3% in the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after purchasing an additional 6,362 shares during the period. Finally, American Century Companies Inc. raised its holdings in shares of uniQure by 14.6% in the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 8,642 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.